Approved labelLanreotide injection prescribing information for acromegaly, GEP-NETs, and carcinoid syndrome
PopulationAdults covered by the approved lanreotide indications
DoseAcromegaly starts at 90 mg every 4 weeks for 3 months before response-based adjustment. GEP-NET and carcinoid-syndrome dosing is 120 mg every 4 weeks.
RouteDeep subcutaneous injection in the superior external quadrant of the buttock by a healthcare provider
FrequencyEvery 4 weeks
DurationLong-term use within the approved indication with label-directed monitoring
PreparationReady-to-use single-dose prefilled syringes containing 60 mg/0.2 mL, 90 mg/0.3 mL, or 120 mg/0.5 mL; no reconstitution.